March 7, 2025 04:43 AM ESTUpdated 01:38 PM

J&J axes Phase 3 depression program due to ‘insufficient efficacy’ shortly after Neumora’s study fail

Kyle LaHucik

Senior Reporter

Johnson & Johnson scrapped its Phase 3 program for aticaprant, an experimental and new type of major depressive disorder drug, following “insufficient efficacy,” the pharma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J axes Phase 3 depression program due to ‘insufficient efficacy’ shortly after Neumora’s study fail

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Q&A: David Liu talks about science under pressure, teases “disease-agnostic” gene editing

Q&A: A conversation with GLP-1 co-discoverer Jens Juul Holst on the future of incretin-based drugs

Trump administration leaves obesity coverage expansion out of new Medicare rule

Secretive Chinese startup begins first-ever clinical trial of circular RNA therapy

Marks was asked to provide non-existent vaccine risk data: WSJ

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

J&J ax­es Phase 3 de­pres­sion pro­gram due to ‘in­suf­fi­cient ef­fi­ca­cy’ short­ly af­ter Neumo­ra’s study fail

Senior Reporter

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

J&J axes Phase 3 depression program due to ‘insufficient efficacy’ shortly after Neumora’s study fail